Exagen Inc. to Participate in Fourth Quarter Investor Conferences
08 nov. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following fourth...
Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022
31 oct. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022,...
Exagen Announces Appointment of John Aballi as CEO
17 oct. 2022 09h00 HE
|
Exagen Inc.
SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who...
Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer
04 oct. 2022 08h25 HE
|
Exagen Inc.
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as...
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
20 sept. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American...
Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients
01 sept. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that its collaboration with Dr. Iñaki Sanz at Emory...
Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA
04 août 2022 16h06 HE
|
Exagen Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to...
Exagen Inc. Reports Second Quarter 2022 Results
04 août 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2022. ...
Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
25 juil. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42nd Annual...
Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022
21 juil. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after...